Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, highlights key themes from this year’s ADA Scientific Sessions, including significant progress in obesity treatment, type 1 diabetes, technology, health disparities, and innovation. Notable studies, such as the FLOW trial on GLP-1 receptor agonists for kidney outcomes and the Surmount OSA study on sleep apnea, were discussed.
Dr. John Buse shared insights from the Catalyst Study, revealing a high prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes, potentially reshaping future screening and treatment guidelines.
-
Alfredo Jaume1yrFascinating studies and gives us another armament to control DM, HTN ASVD , CKD hopefully in the near future thanks
